SCHEMBL14937993

SCHEMBL14937993

Cn1nccc1C(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.68
RAB9A P51151 6/20 0.68
CYP1A2 P05177 2/20 0.68
CYP2C19 P33261 2/20 0.68
CYP2D6 P10635 1/20 0.68
SMN1; SMN2 Q16637 3/20 0.63
FLT1 P17948 3/20 0.62
KDR P35968 3/20 0.62
ALDH1A1 P00352 2/20 0.57
NAMPT P43490 1/20 0.57
PKM P14618 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
TRPV1 Q8NER1 1/20 0.52
NPSR1 Q6W5P4 2/20 0.51
TSHR P16473 1/20 0.51
HSD17B10 Q99714 1/20 0.51
GMNN O75496 1/20 0.51
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14937486 0.83 TLR7 (0.51) NPC1RAB9ACYP1A2CYP2C19CYP2D6
SCHEMBL20741555 0.81 NPC1 (0.73) NPC1RAB9ACYP1A2CYP2C19CYP2D6
SCHEMBL20741566 0.81 NPC1 (0.73) NPC1RAB9ACYP1A2CYP2C19CYP2D6
SCHEMBL20741558 0.81 NPC1 (0.46) NPC1RAB9ACYP1A2CYP2C19CYP2D6
SCHEMBL20661001 0.80 NPC1 (0.47) NPC1RAB9ACYP1A2CYP2C19CYP2D6
SCHEMBL26657255 0.79 GRM4 (0.47) NPC1RAB9ACYP1A2CYP2C19CYP2D6
SCHEMBL6059993 0.76 POLB (0.58) ALDH1A1MEN1KMT2ATRPV1NPSR1
SCHEMBL14938017 0.75 OXTR (0.57) SMN1; SMN2KMT2ATRPV1HTR2A
SCHEMBL20741504 0.75 NPC1 (0.64) NPC1RAB9ACYP1A2CYP2C19CYP2D6
SCHEMBL25591484 0.75 MAPT (0.46) NPC1RAB9ACYP1A2CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
EP-2599775-A1 ETHINYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A NPC1 964/4885RAB9A 1090/4885CYP1A2 904/4885
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE GABRE, GRIN3A, GRIK5 NPC1 2571/4885RAB9A 621/4885CYP1A2 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.